Clinical trials for NSCLC that combine nivolumab or durvalumab anti–PD-(L)1 with ipilimumab or tremelimumab anti–CTLA-4 as mentioned above have shown no or only modest additional clinical benefit compared to monotherapy PD-(L)1 blockade (65). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.